Advancements in Preservative-Free Ketamine Therapies by NRx Pharmaceuticals
Update: 2025-10-16
Description
NRx Pharmaceuticals, a NASDAQ-listed company, is making strides in the development of preservative-free ketamine-based therapies by refiling an application for KETAFREE and advancing NRX-100 for suicidal ideation in depression. CEO Dr. Jonathan Javitt highlighted new pipeline developments and collaborations, showcasing the company's commitment to bringing these therapies to market.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
